squibb - Search News

News

Bristol Myers Squibb Cuts Full-Year Adjusted View

Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)

Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after earnings. Read the latest stock analysis here.

Yahoo Finance · 5h

Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article

The Wall Street Journal on MSN · 11h

Bristol Myers Squibb Cuts Full-Year Adjusted View, but Raises Revenue Expectations

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a charge related to its BioNTech partnership.

PE Hub3h

Accel-KKR, Carlyle, Vistria target home care software; Bain Capital, Bristol Myers Squibb launch autoimmune biopharma biz

Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...

21h

2BMY : Bristol-Myers Squibb Unusual Options Activity For July 31

Out of all of the special options we uncovered, 26 are puts, for a total amount of $1,771,839, and 16 are calls, for a total amount of $839,064. Taking into account the Volume and Open Interest on ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

Bristol Myers Squibb Cuts Full-Year Adjusted View

Trending now